Undisclosed Symbiont-Derived Program(s)

About Holoclara

Holoclara is an early-stage biotech leveraging the 'hygiene hypothesis' to create a new class of drugs from symbiotic worm-derived molecules. The company's platform aims to treat a wide range of immune-mediated and metabolic chronic diseases by restoring evolutionary signals missing from the modern human biome. Led by a CEO with an MD/PhD and a team of seasoned industry veterans, Holoclara is building a preclinical pipeline with backing from venture capital firms like Bold Capital and Horizons Ventures. The company represents a high-risk, high-reward venture targeting large, underserved markets in autoimmunity and inflammation.

Therapeutic Areas